The genetic manipulation of mice has become an essential and elegant method for studying the function of proteins in physiology, and for testing the veracity of information obtained from cell culture experiments. During the past few years, a variety of transgenic and knockout mouse models of PKB (protein kinase B)/Akt have been generated and investigated. In this paper, we focus on the phenotypes of these PKB/Akt overexpression and mutant mice that may help to elucidate the functions exerted by PKB/Akt in mammals.
Introduction
Three PKB (protein kinase B)/Akt isoforms have been identified in mice and humans (for reviews, see [1] [2] [3] [4] ). These three PKB/Akt proteins, although encoded by distinct genes localized on different chromosomes, have approx. 80% amino acid identity and similar domain structures. Moreover, the differences between corresponding isoforms in humans and mice are subtle (between two and ten amino acid changes), which makes it feasible to determine the functions of PKB/Akt kinases in human physiology by studying them in the mouse.
Stimulation by numerous growth factors, cytokines, hormones and neurotransmitters can activate PKB/Akt in a phosphoinositide 3-kinase-dependent manner (reviewed in [2, 4] ). Through receptor tyrosine kinases, these stimuli cause phosphoinositide 3-kinase activation, and generation of the membrane phospholipid PtdIns(3,4,5)P 3 . PtdIns(3,4,5)P 3 then recruits PKB/Akt to the membrane, where it becomes phosphorylated at Thr 308 and Ser 473 (for PKBα/Akt1) by two upstream kinases, phosphoinositide-dependent kinase 1 and a yet to be identified Ser 473 kinase. These processes of membrane targeting and activation of PKB/Akt can be facilitated and mimicked by adding the myristoylation signal sequence of Lck/Src to the N-terminus of PKB/Akt (Myr-PKB/Akt) or by mutation of the two regulatory sites of PKB/Akt to acidic residues (PKB T308D/S473D in PKBα/Akt1) [4, 5] . Myristoylation of PKB/Akt promotes constitutive membrane attachment and activation, and the T308D/S473D double mutant of PKB is constitutively active [4, 5] . Based on these observations, Myr-PKB/Akt and PKB T308D/S473D have been commonly used for vector construction to generate transgenic mice [5] .
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PKB/Akt transgenic mice

Overexpression of PKB/Akt in tissues
The first PKB/Akt transgenic mouse model was reported in 2000 [6] . Since then, more than 10 PKB/Akt transgenic mouse lines have been produced. Constructs of PKB/Akt and the tissues targeted are summarized in Table 1 . At least two mouse lines have been generated for the thymus, heart, pancreas and mammary glands. A single line has been generated for the prostate. Tissue-specific promoters were used to drive overexpression of PKB/Akt in these different tissues. PKB/Akt was either myristoylated for membrane targeting (activation) or mutated to double Asp (T308D/S473D) for constitutive activation.
Hypertrophy and increased contractility with PKB/Akt overexpression in the heart
The α-MHC (α-myosin heavy chain) promoter has been utilized extensively to drive transgenic expression exclusively in cardiac myocytes [23] . Three of the four PKB/Akt transgenic mouse lines directly use this promoter to drive PKB/ Akt overexpression in the heart. In the fourth line, PKB/Akt transcription is under the control of a tetracycline-responsive promoter that reacts to α-MHC-directed expression of the tetracycline-controlled transactivator [7] [8] [9] [10] [11] . The most readily apparent phenotype of these mice was sudden death of some founders with massive cardiac dilatation [7] . Viable derived transgenic mouse lines showed cardiac hypertrophy, with an approx. 2-fold increase in heart weight. The increase in heart weight was associated with larger cardiac myocytes [7, 9, 10] . These mice also showed a remarkable increase in cardiac contractility and a reduction in infarct size after ischaemia/reperfusion compared with wild-type controls [7, 10] . Overexpression of PKB/Akt in the heart also caused higher p70 S6K phosphorylation, and reduced AMP-activated protein kinase activity [7, 9, 11] .
The transcriptional effects of this chronic activation of PKB/Akt in the heart were analysed using DNA microarrays to determine altered gene expression profiles. Of the differentially expressed genes, up-regulation of insulin-like growth factor-binding protein-5 and down-regulation of PPARγ (peroxisome proliferator-activated receptor γ ) coactivator-1 and PPARα suggest that these may have antiapoptotic and survival effects in the heart [7] . Overall, these results demonstrate that PKB/Akt is an important modulator of heart growth. On the other hand, this also implies that sustained or increased PKB/Akt activity in the heart is one of the causes of cardiac hypertrophy under pathophysiological conditions such as hypertension.
Early onset of thymic lymphomas induced by overexpression of PKB/Akt in T cells
The first reported PKB/Akt transgenic mouse line expressed a constitutively active form of PKB/Akt in T lymphocytes [6] . Thereafter, two groups generated almost exactly the same mice to ask questions from different angles [13, 14] . Both groups reported the development of lymphomas at an early age, and that the majority of the mice died between days 100 and 200. Tsichlis' group [13] was attempting to determine the mechanism of tumour induction by constitutively active PKB/Akt, while Thompson's group [14] focused on the metabolic consequences of activation of PKB/Akt in T cells.
In their Myr-PKB/Akt transgenic mice, Tsichlis' group [13] first observed, prior to tumour formation, that thymocytes were larger than in non-transgenic controls, although thymus size was the same because of fewer cells. Based on this, they hypothesized a thymus-intrinsic mechanism for maintaining the size of the thymus by restriction of the cell proliferation driven by oncogenic Myr-PKB/Akt. Failure of this size regulation promotes cell proliferation and gives rise to an enlarged neoplastic thymus (lymphoma). To test this hypothesis, they isolated fresh thymocytes from transgenic and control thymus glands and found that the cell cycle profiles were not altered in transgenic thymocytes, which expressed low levels of cyclin D3. Nevertheless, once in culture, these transgenic thymocytes showed increases in both cell cycle progression and cyclin D3 levels, probably due to the release of thymus-intrinsic restriction mechanisms. Moreover, freshly isolated thymocytes from the lymphomas had higher levels of cyclin D3. These results supported their hypothesis for tumour induction in Myr-PKB/Akt thymus: constitutively active PKB/Akt can bypass the intrinsic size control mechanisms and cause tumorigenesis. This model of tumour development with increased PKB/Akt activity is intriguing, and should help our understanding of the oncogenic functions of PKB/Akt.
Other groups found that overexpression of PKB/Akt in T cells could influence the positive and negative selection of thymocytes, and the survival, metabolism and activation/ proliferation of T cells [6, 12, 14, 15] . Furthermore, cross-talk was demonstrated between PKB/Akt and important T cell receptor downstream molecules modulating the threshold of thymocyte selection and T cell activation [15] . These observations are similar to the phenotypes displayed by Pten heterozygous mice (where PTEN is phosphatase and tensin homologue deleted on chromosome 10), which have high PKB/Akt activity and develop auto-immunity (production of nuclear antibodies and deposition of immune complexes in the glomerulus) and lymphomas, re-inforcing the proposed role of PKB/Akt in tumorigenesis associated with the Pten mutation [24] .
Fatty milk synthesis in the mammary gland with PKB/Akt overexpression
PKB/Akt expression levels increase in the mammary gland during mouse pregnancy, and more dramatically (12-fold) at the onset of lactation [18] . This suggests important roles for PKB/Akt in mammary gland development and during lactation. After initiation of involution, the levels of PKB/Akt start to decrease, and they remain low during involution [16] [17] [18] [19] . Using the mouse mammary tumour virus promoter, three groups generated transgenic mice with PKB/Akt overexpression in the mammary gland. Initially, they all reported delayed involution of mammary glands in these mice [16] [17] [18] [19] . Involution results from apoptosis of the epithelium in the mammary gland, and overexpression of PKB/Akt could oppose this process by promoting epithelial cell survival [16] [17] [18] [19] .
Intriguingly, a subsequent study of these mice found that females produced fatty milk with excess lipids [18] . The fat content of milk from these lactating transgenic mice was as high as 65-70% by volume, compared with the 25-30% for milk from wild-type mice. Overexpression of PKB/Akt in the mammary gland promoted synthesis of lipids in epithelial cells from early pregnancy until lactation. As a result of lipid accumulation in the mammary gland, the milk was too viscous for sucking by the pups, and growth of the mice was retarded over the first 9 days of lactation. These findings suggest that PKB/Akt regulates lipid metabolism in the mammary gland [18] .
Tumour formation was not detected during a long period (over 1 year) of observation of the mammary glands of these mice [16] . Previous studies found a correlation between increased PKB/Akt activity and transformation in the mammary gland [25] . Recent reports have confirmed this relationship by showing that PKB/Akt phosphorylated p27 on Thr 157 , and that phosphorylated p27 relocated from the nucleus to the cytoplasm devoid of its growth inhibitory properties, thereby allowing breast cancer cell proliferation [26] [27] [28] . This discrepancy suggests that other mechanisms in combination with high PKB/Akt activity cause tumorigenesis in the mammary gland.
Hypertrophy, hyperplasia and hyperinsulinaemia of pancreas with PKB/Akt overexpression
Overexpression of PKB/Akt in islet β cells of the pancreas using the rat insulin II promoter was reported by two groups, and both made similar observations [20, 21] . "Three hypers of hypertrophy, hyperplasia and hyperinsulinaemia" was the most suitable and concise description of these mice, as expressed in the title of one publication [21] . Transgenic expression of PKB/Akt gave rise to larger islets in the pancreas due to increases in both cell size and cell number. Therefore it was concluded that high levels of PKB/Akt caused hypertrophy and hyperplasia of islets [20, 21] . As a result of the islet mass increase, insulin secretion was elevated and these mice were resistant to streptozotocin-induced diabetes. However, the high levels of insulin in blood had little effect on the levels of glucose. These observations indicated that PKB/Akt activation could affect islet β cell mass by altering cell size and cell number, and impact on insulin production [20, 21] . This implicates PKB/Akt in insulin action and diabetes, as discussed below [29] . Moreover, PKB/Akt could possibly be used to expand islet β cells for therapeutic purposes.
Neoplasia induced by overexpression of PKB/Akt in the prostate
A recent report added a new mouse line to the already long list of PKB/Akt transgenic mouse models [22] . This mouse strain showed PKB/Akt overexpression in the prostate initiated by a promoter from probasin, a specific protein expressed in the prostate. This latest mouse line provides new evidence that activation of PKB/Akt in epithelial cells can be oncogenic, and supports previous studies with Pten mutant mice. Pten mutant mice have elevated PKB/Akt activity, which is possibly responsible for the development of prostate cancer in these mice [22] . Given the ability of PKB/Akt prostate transgenic mice to recapitulate human prostate cancer, it may be a useful model in which to study the role of PKB/Akt in prostate epithelial cell transformation, and to develop therapeutic strategies for this disease.
PKB/Akt combination tumour models and others
As mentioned above, chronic activation of PKB/Akt in mice failed to induce tumour formation in tissues such as pancreas and mammary gland, suggesting that activation of the PKB/Akt signalling pathway alone is not sufficient to initiate transformation in these tissues. It has become evident that malignant alteration involves a complex of signal transduction processes, including multiple onco-proteins and tumour suppressors such as Ras, Myc, PKB/Akt, Her-2/Neu, p53 and PTEN [30] . Tumorigenesis results from synergistic interactions of these proteins.
Cellular transformation using a constitutively active PKB/Akt in combination with another oncoprotein was first reported by Holland and colleagues [31] . They transferred active Ras and/or PKB/Akt to neural progenitors in mice and found that neither Ras nor PKB/Akt alone was able to cause GBM (glioblastoma multiforme) in the brain. Nevertheless, together they induced high-grade gliomas with features similar to human GBMs [31] . Recent research results from Varmus' group [30] confirmed these observations. In a mouse model for ovarian carcinoma, even the combination of the three oncogenes c-myc, K-ras and Pkb/Akt was insufficient to induce a tumorigenic state in wild-type p53 mice. However, once introduced into p53-deficient mice, the addition of any two of the three oncogenes transformed cells [30] .
Other experiments performed in mice involved retroviral delivery of PKB/Akt to lungs, mesenchymal stem cells and femoral arteries [32] [33] [34] . Administration of PKB/Akt into vascular endothelial cells promoted angiogenesis [34] , protected against oxidant-induced injury when introduced into the lung [32] , and prevented remodelling and restored the performance of infarcted hearts when delivered to stem cells [33] . These studies have unveiled novel physiological functions of PKB/Akt, and illustrate the potential of PKB/Akt for gene therapy.
To summarize these observations on transgenic mice with PKB/Akt overexpression in a variety of tissues and organs, it is obvious that PKB/Akt promotes both cell proliferation and cell growth apart from its anti-apoptotic properties. Depending on the structure and characteristics of the tissues, sustained high PKB/Akt activity alone could be sufficient to cause transformation. Alternatively, it may contribute to tumour induction after integration with other effectors.
PKB/Akt knockout mice
The effects of gene ablation of PKB/Akt isoforms are summarized in Table 2 .
Pkbα/Akt1 mutant mice: life is difficult from the beginning Initially, two groups reported that Pkbα/Akt1 mutant mice were small and had increased spontaneous apoptosis in the thymus [35, 36] . In parallel, we wanted to understand why these mice were born smaller than their wild-type littermates and had increased neonatal mortality (approx. 40%). We examined the development of embryos in the uterus, and first determined at what gestational stage the mutant embryos become growth retarded. This led to the discovery of small placentas and the small embryos of mutant mice [37] .
As the growth of an embryo depends on the placenta from the middle of gestation, reduced effectiveness of the placenta due to smaller size fails to meet the increasing demand of the embryo for nutrients, and consequently restricts its growth. We focused on the role of PKBα/Akt1 in placental development by histological and biochemical analysis. We found that PKBα/Akt1 was abundant and the predominant isoform of the three in placenta. As a result of PKBα/Akt1 ablation, spongiotrophoblast cells were found to be almost absent, and vascularization was greatly reduced in mutant placenta. The results suggest that PKBα/Akt1 is necessary for trophoblast differentiation. We concluded that PKBα/Akt1 regulates placental development and maintenance [35] . This does not exclude the possibility that an intrinsic effect of PKBα/Akt1 in the embryo also affects foetal growth.
Pkbβ/Akt2 mutant mice: severe diabetes
The phenotype of Pkbβ/Akt2 mice was more striking [29, 38] . These mice developed severe diabetes, which is consistent with the expected function of PKB/Akt, especially PKBβ/Akt2. Insulin action was blocked in the absence of PKBβ/Akt2 and the mice were insulin resistant, with hyperglycaemia, hyperinsulinaemia and glucose intolerance [29] . An increased insulin concentration in serum (hyperinsulinaemia) may result from compensation by the β cells of the decreased responsiveness to insulin in peripheral tissues [29] . Consistent with this, it was reported that pancreatic islet mass and number in PKBβ/Akt2-deficient mice were increased [29] . A later study with PKBβ/Akt2-null mice on a different genetic background failed to observe the compensatory increase in pancreatic islet mass and number [38] . Instead, a progressive β-cell failure in a large number of male PKBβ/Akt2-null mice by the age of 5-8 months was found [38] . Moreover, the mice exhibited mild growth retardation and an age-dependent loss of adipose tissue (lipoatrophy). These observations suggest that PKBβ/Akt2 plays critical roles in glucose metabolism, adipogenesis and maintenance, β-cell function and animal growth. Both PKBa/Akt1 and PKBβ/Akt2 are important mediators of organismal growth [38] .
By quantitative reverse transcription-PCR, we analysed the expression levels of the three PKB isoforms in different mouse tissues [37] . PKBβ/Akt2 appeared to be the most abundant isoform in insulin-responsive organs and tissues, i.e. liver, skeletal muscle and fat [37] . This unique tissue distribution may distinguish PKBβ/Akt2 from the other two isoforms in its primary role in glucose homoeostasis, and may explain the distinct knockout phenotype of Pkbβ/Akt2.
Pkbγ /Akt3 mutant mice: small brain Pkbα/β (Akt1/2) double mutant mice: severe growth deficiency
Given the essential role of PKB in survival, the availability of viable mice with a single PKB knockout suggests mutual compensation of function among the three isoforms, and that compound knockout of two genes may have severe developmental and survival consequences. This is indeed the case. DKO (double knockout) mice of Pkbα/β (Akt1/2) could develop to term, but died shortly after birth, showing more obvious phenotypes than single knockout mice [39] . The DKO mice were much smaller than wild type, with impaired skin development, skeletal muscle atrophy and abnormal bone development. PPARγ , a master gene in adipogenesis, could not be induced in embryonic fibroblasts from the DKO mice. Consequently, the differentiation of DKO mouse embryonic fibroblasts into adipocytes was blocked. This suggests that PPARγ is under the control of PKB [39] .
The delayed or impaired development of tissues in DKO mice may be attributable to placental defects. Pkbα/γ (Akt1/3) DKO mice are embryonic lethal, and the phenotypes displayed by DKO placentae were more severe than in the single Pkbα knockout. We presume that the death of DKO (α/γ ) embryos is a consequence of placental insufficiency. Further studies will be performed to test this hypothesis.
Summary
Overexpression or deletion (gain of function and loss of function respectively) of PKB/Akt in mice leads to distinct and intriguing phenotypes. The investigation and characterization of such mice have provided novel insights and extended our understanding of the function of PKB/Akt in mammals. The regulation of cell proliferation and growth (cell size) by PKB/Akt, if disrupted, may induce neoplasia and transformation in some tissues, or lead to impaired growth and development of mice, as well as aberrant glucose metabolism and, eventually, diabetes. The results obtained from these studies on mice have further confirmed the essential functions of PKB/Akt in numerous cellular and physiological processes.
